Mammalian audi tory ha ir cells have minimal capacity for repa ir or rege ne ration after a variety of insu lts, including acoustic trauma and aminoglycoside expo sure. A ltho ugh fe tal tissues hav e a greater potential f or repair and regeneration than adult tissues, there have been no repo rted studies on fe tal hair cell response to inju ry in mammals. The purpose of this research was to investigat e the effec ts ofloca l applica tion ofkanamycin onfetal lamb coc hlear hair cells.
Experimental Protocol
There were three phases to this exper iment. In phase I, 2 anima ls were used to determi ne if the trans-roundwindow injection of ka na myc in wo uld cause deafness (and presumab ly hair ce ll destru ction ) in the fetu s. These animals were sacrificed afte r audiologic testing, but their tem poral bones were not harvested for histo patholog ic study.
In phase II, 6 animals underwent placement of auditory electrodes afte r kanamyc in was injected into the left coc hlea as described below. These anima ls unde rwent serial electrocochleography beginning on postop erat ive day (POD) I. The coc hleae were to be harvested for histopathologic exa minatio n durin g the seco nd week after kanamycin injection.
Phase III was performed to minim ize the rate of spontaneous abor tion see n in chronically instrumented animals. These final 3 animals were deafen ed, as in phase II, but were not instrum ented for chronic audiologic testing. These fetuses were reimplanted in the uteru s, and no further manipul ation was done until I month follo win g surge ry, when the animals were euthanized and their temporal bones harvested . Anim als in this phase provided inform ation on the late effe cts of ka namyci n perfusion on the hair ce lls.
Surgery
Ewe s were fasted, anesthetized with halothane by mask, and oro trac hea lly intubated. A midl ine hysterot om y was performed, and the fetal head was delivered. Both middl e ear s were expose d via a postauricular inc ision. The ventral bull ae were opened widely, expos ing the basal turn s of the coc hleae and the round windows . The right ear was used as a contro l; no manipul ation was performed beyond exposi ng the round window and placing the ro und-window ball electrode. The left round windo w was pierced with a 27-gauge needle. A sample of 15 ml of perilymph ' was wit hdraw n, and the cochlea was perfused with an equal volume of kanamycin solutio n (200 mg/ml ).
Coo ner ball-tip electrodes were placed on the round window . 14 The round-window niche was then packed with a piece of Gelfoam that had been soaked in I ml of kana myc in (200 mg/ml ). Reference and ground electrodes were placed in the skull and the dorsal neck muscles, respect ively. Electrodes were sec ured to the skull with methyl methacrylate. A bone oscillator, which functioned as an in utero sound transducer, was secured to the dorsal skull with screws, ligatures, and meth yl methacrylate. "
Incisio ns were closed with silk sutures. The fetal head was placed back into the uteru s, and the hysterotomy was closed wit h permanent sutures. Sodium ampicillin (500 Volume 78 , Number 3 mg) was instill ed into both the amn iotic fluid and the peritone al cavi ty. Electrodes were tun neled from the hysterot om y incision up through a stab incis ion on the ewe's flank and housed in a clot h pouch. After recovery from anesthes ia, the ewes were placed in large cove red pens ju st outside our laboratory.
Auditory Evaluation
Aud itory testin g was conducted as the ewes stood in large cart s. Hearing thresholds were determin ed with click-e voked co mpo und actio n potent ials (CAPs) , using previously described protocols." Broadband clicks with a O.l-ms duration were presented with alternating polarity at a rate of 5/sec. The bone osci llator (Radioear, #B70A) output was meas ured with an acce lero meter (Bruel and Kjaer model 800 I ; Marl borough , Mass.) fixe d directly to its vibr atin g surfa ce prior to implant ation. Electrica l inputs from the electrodes were digitized over 10 ms, averaged over 200 trials, and store d on disk (Biosig , Tucke r-D avis Techn ologies; Gainesville, Fla.). Thresholds were determ ined by attenuating stimulus intensit ies by 10-dB inc rement s from a 100-dB nHL (human) maximum until the waveform was lost, then raise d by 5-dB increments until the waveform was reestablished.
Histopathology
Animals were euthanized via an umbil ical intravenous injection of sodium pentobarbi tol after cesarean section. The temporal bones were harvested and fixed in 10% buffered formalin. Specim ens were decalc ified with Ca l-Ex solution (Fisher Scientific ; Pitt sburgh). Haircell prep aration s were performed with rhodamine-co njuga ted phalloid in labelling (Mo lecular Prob es, Inc. ; Euge ne, Ore.) as previou sly described .15 Semiquantitative hair cell counts were based on stain intensity and struc tura l co mpletene ss. Because of the complex anatomy of the sheep cochlea , hair cell counts are present ed in a semiqua ntitative scale (range: 0 to 4) and describ ed in detail in tabl e I.
Results

Phase I
Two ani mals were used to determ ine whet her kanamycin inje cted through the round window would effec tively deafen the experimental ear. On POD I, both an imals had reproducible CAPs in the contro l ear and no measurabl e CAPs in the kanamycin-treated ear. One animal lost its electrodes before furth er testing co uld be performed, but the second anim al was serially tested on seve n occasions over a 28-day period . A reproduc ible CAP with thresholds ave rag ing 70 dB was reco rded in the co ntro l ear, and no measur abl e CAP was seen in the experimental ear.
Phase II
Once the kanamycin injection technique had been shown to cause profound hearing loss, 6 more fetuses (sheep #1 - kanamyci n ototox icity as introd uced in this study .
Aminog lycosides are fre quently used antibiotics that have well-known toxic effects on hair cells . Although the molecul ar mechanism of injury is not known , it is thought to involve mult iple intracellular reaction s, including mitoch ond rial protein synthes is, ion transport, and DNA and RNA synthesis .18 A minog lycos ide mod els of ototox icity are widely used in the study of hair cell injury and regeneration.>'
With the exce ptio n of I animal, kanamyc in injection directl y into the fetal coc hlea consistently resul ted in profound hearin g loss. Although kanamyci n perfusio n successfully deafened the treated ea rs, hair cells were fo und to be intact in these ears in both ea rly and late gro ups. Th e pres ence of many normal hair cells in the health y early-phase anima ls (e.g., #2, # 3, and #6) may support the relative res istance to kanam ycin ototoxicity in the fe tal sheep at this ges tatio nal age. Massive hai r cell loss was found onl y in animals that ex per ience d fetal dis tress and spontaneo us abor tion . Th e loss of hair cells in these distressed ani ma ls cou ld eas ily be secondary to coc hlear hypoxia." Hence, the result s with the distressed anima ls should not be co mpared wit h those of otherwise health y fetuses.
Th e molecular mec hanisms of ami nog lycoside ototoxicity are not yet fully understood. Recen t theor ies postulate that aminog lycosi des do not become harmful until they are metabolized into a tox ic metabolite." In the fetal env ironmen t, eve n less is know n abo ut the biochemical basis of aminog lycoside ototox icity . Perhaps the fetal environment inh ibits the for mation or increase rate of clearance of the toxic metabol ite, thereb y makin g the fetu s relatively resistant to the toxicity of the dru g.
It was ass umed that a dose of kanam ycin sufficient to pro foundly deafen an animal would also be adequate to ca use hair cell death. McMullen and Glaser have show n a co mplete loss of auditory brainstern respon se fro m a micro injectio n of ka namycin (333 mg/ml) throu gh the Temporal bon es were harvested be tween POD 4 and POD 14 . Three ewes (#1, #4, and #5) ex per ience d a premature onse t of labor, one of whic h res ulted in fetal death prior to temp oral bone harvestin g. Th e degree of hypoxic damage sus tained by the coc hleae of these animals is uncertain . Hair cell counts for all shee p are show n in table 2. Tem poral bones that were harvested after the premature onset oflabor showed no evi de nce of hair cells . Hair cells were abundant in shee p #3, which had a measurable CA P at the time of sacr ifice . Su rprisi ng ly, hair cells were also intact in 2 animals (#2 and #6) that did not have measurable CAP s prior to sac rifice.
Phase III
Th e fina l 3 fetuses (#7, #8, and #9) underwent transround-window injection of kanamycin without placement of electrodes for auditory testing. Thi s allowed for longer surv ival after deafening (and less chance of spo ntaneous abor tio n). Accordingly, audi tory testing was not performed in these animals. All 3 of these animals had many demonstrable hair cells (table  2) .
*SQHC =semiquantitative hair cell counts (table 1) .
Discussion
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. In anIS-month carci nogenicitystudy in mi ce and a 2-year study In rats loratadine was administered in the diet at doses upto 40 mg/kg (mice) and 25mg/kg (rats). In the carcinogenicity studies pnarrnacokinetic assessments werecarried outto det ermineani mal exposureto the drug. AUC data demonstrat ed that the exposure of mice gi ven 40 mg/kg of loratadi ne was 3.6 (Ioratadine) and 18 (active metabolite) times higherthanin humans given themaximum recommended dall y oral dose. Exposure of rats given 25 mg/kg of loratadine was 28 (Ioratad ine) and 67 (active metabolite) times higher than in humans giventhemaximum recomm ended dal ly oraldose. Mal emi cegiven 40 mg/kg had a significantly higher incidence of hepatocellular tumors (combined adenomas and carcinomas) than concurrent controls. In rats, a significantly higher incidence of bepatocellutar tumors (combined ade nomas and carcinomas).was observed In males given10 mg/kg andin males and femal es given 25 mg/kg. Theclinical significance of these findings during long-term use of loratacine IS not known.
Two-year feeding studies in mice and rats condu cted under the auspices of the National Toxicology Programs (NTP) uncovered no evidence of carcinogenic potential of ephedrinesulfate at dosesupto 10 and 27 mg/kg, respectivel y (approxi mately 16% and 100% of the maximum recomm end ed human daily oral dose of pseudoephedr ine sulfate ona mg/m' basis).
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REPORTEDADVERSEEVENTSWITHANINCIDENCE OF
Patient s who are or may become pregnantshould be told that this product should be used in pregnancy or during lactation only if the potential benefit justifies the potenti al risk to the fetus or nursing infant.
Patientsshould be instructed not to breakor chew thetabl etand to take it with a full glass of water (see PRECAUTIO NS: General , ADVE RSE REACTIONS, OOSAGE AND AOMINISTRATIO N). Orug Interactions: No specific interacti on studieshave been conducted with CLAR ITIN-D 24 HOUR Extended Release Tablets. However, loratadine (10 mg once daily) has been safely coa dmlnlstered with therapeutic doses of erythromycin, cimetidine, and ketoconazole in controlled clinical pharmacology studies. Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of thesedrugsin normal volunteers (0. = 24 in each study), there were no clinically rel evant changes in the safety profile of loratad ine, as assessed byelectroca rdiograph ic paramete rs, clinical labor atorytests, vital signs, and adverse events. There were no significant effects on QT, intervals, and no reports of sedation or syncope. Noeffectson pl asma concentrationsof cimetidine or ketoconazole were obse rved. Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadmi nistratio n of loratadine relativeto thatobserved with erythromycin alone. Theclinical releva nce of this difference is unknown. These above findings are summarized in the followingtable:
Effects ova l window in neonatal rabbit s. A nearly co mplete loss of outer hair cells in the kanamyc in-dea fened ears was see n after 60 days." Alt houg h we inj ected a co mparable dose of ka namycin thro ugh the round window in the fetal lamb , hair ce ll destru ction was min imal co mpared with that seen in the rabbits. Th ere are no previous studies that eva luated the effect of ka namyc in on the middle or inner ear of fetal sheep. Our findings most likely represe nt a relative resistance to kanam ycin in the fetal sheep model. We hypothe sized that maximum hair ce ll destru ction would be evi dent in the early gro up and that hair cell repair or rege neration-if any-would be more likely in the late group, as previo usly reported by Forge et al.?Hair ce ll integrity was better in the animals that were sac rificed I month after kanamyci n perfusio n than in the animals that were sacrificed within 2 week s of treat ment. Th ese findings ma y be secondary to repair or regeneration of auditory hair cells with time. How ever, the presence of hair cells throughout the basal turn in the healthy fetuses that were sacrificed within 2 weeks after inj ury (early gro up) and the recovery of hearing in I of these animals sugges ts that kanamycin caused sublethal injury and allowed subsequent repair, but not regeneration, of auditory hair ce lls.
In avian mode ls, which demonstrate the grea test capacity for hair cell regeneration, sign ificant recov ery of func tional hearing has not been see n until 16 to 20 weeks after intram usc ular ge ntam icin treat ments.' Hence, recovery of CAP responses within 6 days in I kanamycintreated fetal ear further suppor ts a relative resistance of the fetal hair cells to aminog lycos ide toxicity.
Summary
Hearing loss is usually cau sed by injury to the coc hlear hair cells. Rege neration of damaged hair cells has not been cle arly demonstrated in mammals. In this study, we sought to eva luate the response of fetal hair cells to toxic aminog lycos ide perfusion. We tested fetal tissues because they have the greatest poten tial for rege nera tion . Injection of kanamycin into the coch lea caused deafness in all but I fetal Iamb . Sem iquantitati ve hair cell anal ysis revealed that hair cells were intact in all animals except those tha t experienced fetal distress (hy poxia) prior to sacr ifice. Th e presence of intac t hair cells in the fetuses Figure 1 . Rhodam ine-conjugated phalloidin-stained surface preparation of a fetal cochlea that had been injected with kanamycin 14 days prior to sacrifice (sheep #6).
Volume 78, Number 3 Figure 2 . Rhodamin e-conjuga ted phalloidin-stained surface preparation of a fetal cochlea that had been injected with kanamycin 30 days prior to sacrifice (sheep #7).
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The Osler Institute that were sacrifice d ear ly afte r ka namycin per fu sion sugges ts that sublethal hair ce ll inj ury occ urred. Th e presence of higher hair cell co unts in the fetuse s th at we re sacrificed later afte r kanam ycin perfu sion sugges ts that some degree of repair also occ urred. Th e relative resistance of fet al hair ce lls to kanamycin perfu sion is di stin ctl y different fro m that which has been observed in postn atal mammal s. Th e mec hanis ms resp on sibl e for th is rel at ive ami nog lycoside resistan ce wa rran t further study.
